Biotech Startups

Brinter develops 3D bioprinting technology for regenerative implants. The company serves the medical and biotech industries focused on human repair applications.

2 investors

Brooklyn Health builds objective, sensitive measurement tools for symptoms of neurological and neuropsychiatric disorders, aimed at reducing risk in CNS drug development. It serves the biotech and pharmaceutical sector with a team of clinicians, scientists, engineers, designers, and operators focused on the measurement problem in health.

2 investors

Brown Foods develops lab-grown whole cow milk using cellular agriculture, aiming to produce real dairy without conventional farming for a more sustainable food system.

2 investors

Bugamed Biyoteknoloji, founded in 2017, produces critical raw materials such as atelocollagen, undenatured collagen, hyaluronic acid, silk fibroin, and vegan protein for the pharmaceutical, medical device, cosmetics, and food industries. The company focuses on sustainable biotechnology-based ingredient solutions.

2 investors

Bugworks Research is a drug discovery company developing small molecule therapeutics, including novel antibacterial agents targeting antimicrobial resistance (AMR) across Gram-negative and Gram-positive infections and next-generation immuno-oncology treatments for hard-to-treat tumors. Its research focuses on affordable oral and intravenous therapies for serious hospital and community infections and cancer.

2 investors

BullFrog AI develops AI/ML software for drug discovery that harmonizes fragmented biomedical data and analyzes complex multimodal datasets to identify patient subgroups, drug targets, and biomarkers. It serves biopharma and life sciences teams working on clinical trials and translational research.

2 investors

Bunsen is a creative agency that helps science and deep technology companies develop strategic narratives and design to communicate their innovations to investors and the public. The firm combines scientific expertise, venture capital insight, and creative design to serve founders in biotech, life sciences, and frontier technology sectors.

2 investors

CaaMTech is a pharmaceutical drug discovery company that engineers novel small-molecule psychedelic-inspired therapeutics for mental health treatment through structure-activity optimization and safety screening. The company conducts fundamental research on tryptamine compounds, develops intellectual property, and aims to support the psychedelics industry with scientific foundations and validated drug candidates.

2 investors

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.

2 investors

Cadence provides over-the-counter contraceptive products including morning-after pills, pregnancy tests, and UTI relief kits distributed through convenience stores. The company focuses on improving access to affordable reproductive health products without prescription or insurance requirements.

2 investors

Caffree develops a powdered enzymatic system for precision decaffeination that converts caffeine into theobromine, allowing coffee brands to control caffeine levels without changing flavor. It targets coffee brands, cold brew and RTD beverage manufacturers, and co-packers, integrating into existing production equipment.

2 investors

Caidya provides clinical trial management solutions designed for pharmaceutical and biotech companies seeking to improve trial efficiency and patient outcomes through integrated, patient-centric approaches.

2 investors

CALCIVIS develops the CALCIVIS Imaging System, a chairside diagnostic device that provides real-time assessment of enamel demineralization and tooth decay activity to support preventive dentistry. The FDA-approved and UKCA-marked system is aimed at dental clinicians managing caries and erosion.

2 investors

Calimmune was a Tucson-based biotech founded in 2006 from David Baltimore's research that developed ex vivo gene- and stem-cell-therapy technologies, including an HIV treatment (CAL-1) and a sickle-cell/beta-thalassemia therapy (CAL-H).

2 investors

Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.

2 investors

Calliditas is a biopharmaceutical company developing and commercializing treatments for renal and other conditions, including TARPEYO/Nefecon/Kinpeygo (budesonide) for primary IgA nephropathy and NOX inhibitor candidates such as setanaxib for fibrotic diseases and cancer. It works with commercial partners including Everest Medicines and STADA to bring its therapies to markets such as the US, UK, EU, and China.

2 investors

cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease). The company is advancing the drug into global Phase 2 clinical development.

2 investors

Canomiks is a life sciences company focused on developing treatments and research in diabetes, cardiovascular disease, and related areas, drawing on expertise in pharmacology, genomics, and bioinformatics.

2 investors

Canopy Biosciences (Bruker Spatial Biology) develops spatial biology instruments and assays for analyzing gene expression, RNA, and proteins in tissue samples. The company serves research institutions, academic medical centers, and clinical laboratories studying oncology, biomarker discovery, and disease mechanisms.

2 investors

Canurta develops novel botanical drug candidates, starting with rare polyphenols, using an AI discovery engine that guides compound identification, optimization, GMP-compliant production, and blockchain-based traceability. The company targets disease pathways such as inflammation, oxidative stress, and neurodegeneration (including ALS) across its therapeutic pipeline.

2 investors

Capro-X uses low-capex biofoundries and anaerobic digestion to upcycle food and agricultural waste into caproic acid and related fatty acid-based products, offering a sustainable alternative to palm- and coconut-sourced chemicals. Its outputs serve chemical manufacturing, bioplastics, fuels, food, and flavor/fragrance markets while reducing waste-disposal greenhouse gas emissions.

2 investors

CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.

2 investors

Carbogenics produces biochar from organic waste such as secondary biomass and difficult-to-recycle paper for use in anaerobic digestion, wastewater treatment, soil amendment, and carbon sequestration. The company, based in Edinburgh, operates as a cleantech and circular economy business addressing energy and food sustainability challenges.

2 investors

Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.

2 investors